Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-981 plus pembrolizumab in advanced or metastatic solid tumors
jRCT2031210417Phase 2Completed
- Sponsor
- Takeda
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, open-label trial of subasumstat and pembrolizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), Cervical Cancer (CC) and 2 more (7 arms), sponsored by Takeda. Primary endpoints: Number of participants with one or more treatment-emergent adverse events, Number of participants with dose-limiting toxicities and 5 more. Started Aug 2020; status: completed.
02
Drugs
subasumstatpembrolizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)Cervical Cancer (CC)colorectal cancer (CRC)cutaneous melanoma (CM)
Beyond the preview
Go deeper on jRCT2031210417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210417.